C G Parsons

Summary

Affiliation: Merz Pharmaceuticals
Country: Germany

Publications

  1. ncbi request reprint NMDA receptors as targets for drug action in neuropathic pain
    C G Parsons
    Department of Preclinical Research and Development, Merz and Co GmbH, Eckenheimer Landstrasse 100 104, D 60318 Frankfurt, Germany
    Eur J Pharmacol 429:71-8. 2001
  2. ncbi request reprint Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist: patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones
    C G Parsons
    Department of Pharmacology, Merz and Co, Frankfurt, Germany
    Neuropharmacology 37:719-27. 1998
  3. ncbi request reprint Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization
    C G Parsons
    Department of Pharmacology, Merz Co, Frankfurt am Main, Germany
    Neuropharmacology 38:85-108. 1999
  4. ncbi request reprint Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data
    C G Parsons
    Department of Pharmacological Research, Merz and Co, Frankfurt am Main, Germany
    Neuropharmacology 38:735-67. 1999
  5. ncbi request reprint A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists--in vitro characterization
    K Gilling
    Preclinical Research and Development, Merz Pharmaceuticals GmbH, Frankfurt, Germany
    J Neural Transm 114:1529-37. 2007
  6. ncbi request reprint Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP
    W Zajaczkowski
    Department of Pharmacology, Merz and Co, Frankfurt M, Germany
    Neuropharmacology 36:961-71. 1997
  7. ncbi request reprint Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists
    W Danysz
    Merz Co, Eckenheimer Landstrasse 100 104, Frankfurt, 60318, Germany
    Curr Pharm Des 8:835-43. 2002
  8. ncbi request reprint Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action
    W Danysz
    Department of Pharmacology, Merz Co, Eckenheimer Landstrasse 100 104, 60318 Frankfurt Main, FRG
    Neurotox Res 2:85-97. 2000
  9. pmc Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices
    T Frankiewicz
    Dept of Pharmacology, Merz Co, Frankfurt am Main 1, Germany
    Br J Pharmacol 117:689-97. 1996
  10. ncbi request reprint Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine
    K E Gilling
    In Vitro Pharmacology, Merz Pharmaceuticals GmbH, Eckenheimer, Landstrasse 100, 60318 Frankfurt am Main, Germany
    Neuropharmacology 53:415-20. 2007

Collaborators

  • W Danysz
  • G Rammes
  • B Potier
  • C Jatzke
  • K E Gilling
  • K Gilling
  • M W Jones
  • T Frankiewicz
  • A Jirgensons
  • C Wollenburg
  • M Vanejevs
  • V Kauss
  • W Zajaczkowski
  • P M Headley
  • M McClean
  • G L Collingridge
  • Z I Bashir

Detail Information

Publications12

  1. ncbi request reprint NMDA receptors as targets for drug action in neuropathic pain
    C G Parsons
    Department of Preclinical Research and Development, Merz and Co GmbH, Eckenheimer Landstrasse 100 104, D 60318 Frankfurt, Germany
    Eur J Pharmacol 429:71-8. 2001
    ..Such agents might be predicted to be devoid of CNS side effects at doses producing powerful antinociception at peripheral NMDA receptors...
  2. ncbi request reprint Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist: patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones
    C G Parsons
    Department of Pharmacology, Merz and Co, Frankfurt, Germany
    Neuropharmacology 37:719-27. 1998
    ..The relevance of NMDA receptor antagonism to the anti-Parkinsonian effects of budipine remains to be established...
  3. ncbi request reprint Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization
    C G Parsons
    Department of Pharmacology, Merz Co, Frankfurt am Main, Germany
    Neuropharmacology 38:85-108. 1999
    ....
  4. ncbi request reprint Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data
    C G Parsons
    Department of Pharmacological Research, Merz and Co, Frankfurt am Main, Germany
    Neuropharmacology 38:735-67. 1999
    ....
  5. ncbi request reprint A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists--in vitro characterization
    K Gilling
    Preclinical Research and Development, Merz Pharmaceuticals GmbH, Frankfurt, Germany
    J Neural Transm 114:1529-37. 2007
    ..In view of their relatively low affinity and associated rapid kinetics, they should prove to be useful therapeutics in a wide range of CNS disorders...
  6. ncbi request reprint Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP
    W Zajaczkowski
    Department of Pharmacology, Merz and Co, Frankfurt M, Germany
    Neuropharmacology 36:961-71. 1997
    ..Thus, under conditions of tonic activation of NMDA receptors, uncompetitive NMDA receptor antagonists can paradoxically reverse deficits in learning and synaptic plasticity...
  7. ncbi request reprint Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists
    W Danysz
    Merz Co, Eckenheimer Landstrasse 100 104, Frankfurt, 60318, Germany
    Curr Pharm Des 8:835-43. 2002
    ..and pain (chronic pain, inhibition of tolerance to the analgesic effects of morphine). It turn, this agent has recently entered phase II of clinical trials in alcoholism after a favourable profile seen in phase I studies...
  8. ncbi request reprint Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action
    W Danysz
    Department of Pharmacology, Merz Co, Eckenheimer Landstrasse 100 104, 60318 Frankfurt Main, FRG
    Neurotox Res 2:85-97. 2000
    ....
  9. pmc Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices
    T Frankiewicz
    Dept of Pharmacology, Merz Co, Frankfurt am Main 1, Germany
    Br J Pharmacol 117:689-97. 1996
    ..This is due to its rapid relief of blockade upon depolarization; a property which might explain its promising clinical profile in the treatment of chronic neurodegenerative diseases...
  10. ncbi request reprint Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine
    K E Gilling
    In Vitro Pharmacology, Merz Pharmaceuticals GmbH, Eckenheimer, Landstrasse 100, 60318 Frankfurt am Main, Germany
    Neuropharmacology 53:415-20. 2007
    ..These fast agonist concentration-dependent kinetic properties, in addition to the clear voltage-dependence of memantine, are proposed to be important for the therapeutic tolerability of this compound in the treatment of AD...
  11. ncbi request reprint The in vivo relevance of the varied channel-blocking properties of uncompetitive NMDA antagonists: tests on spinal neurones
    M W Jones
    Department of Physiology, School of Medical Sciences, University Walk, Bristol BS8 1TD, UK
    Neuropharmacology 41:50-61. 2001
    ....
  12. pmc The fraction of activated N-methyl-D-aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole
    G Rammes
    Clinical Neuropharmacology, Max Planck Institute of Psychiatry, Kraepelinstrasse 2, 80804, Munich, Germany
    J Neural Transm (Vienna) 115:1119-26. 2008
    ..It is therefore likely that NMDA receptor antagonists would be able to exert additional therapeutic effects in combination therapy with GRIs...